As healthcare evolves toward more personalized, efficient, and outcomes-driven models, real-world data (RWD) is becoming a cornerstone of transformation. For both hospitals and pharmaceutical companies, investing in RWD isn’t just a technological upgrade – it’s a strategic imperative.
At Sqilline Health, we support healthcare organizations to unlock the full value of their data by combining advanced technology with deep healthcare expertise. Our proprietary Danny Platform plays a central role in this process – automating data structuring, applying semantic standards and AI algorithms, and enabling complex analytics at scale.
Paired with our structured RWD-to-RWE methodology, Danny ensures your data is transformed into actionable real-world evidence (RWE) that is clinically meaningful, regulator-ready, and strategically useful.
What is real-world data?
Real-World Data refers to health-related information collected outside traditional clinical trials – such as electronic health records (EHRs), health documents, laboratory tests, patient registries. When this raw data is structured, validated, and analysed, it becomes real-world evidence (RWE) – the foundation for smarter decisions in care, research, regulation, and commercialization.
At Sqilline Health, we follow a clear, transparent, and adaptable process to turn RWD into RWE. It begins with data quality assessment, followed by clinical and technical alignment, semantic data structuring, and cohort creation for targeted research or clinical trials. These steps are powered by Danny Platform, which automates data structuring, integration, and analytics.
We also emphasize stakeholder engagement and a validation feedback loop, ensuring that the RWD and RWE we deliver is not only accurate and reproducible but also aligned with real clinical and regulatory expectations.
Why RWD matters to hospitals
- Support clinical decision-making
RWD supports precision care by identifying which treatments work best for specific patient populations. It is essential for assessing the true value that health technologies bring to patients and directly supports evidence-based medicine.
- Operational efficiency
Hospitals can use RWD to analyse workflows, reduce avoidable readmissions, and optimize capacity and staffing across departments.
- Clinical trial participation
Hospitals that invest in RWD infrastructure are more attractive clinical trial sites. They can:
- Recruit eligible patients faster
- Engage physicians as investigators
- Gain additional revenue
- Enhance their institutional reputation as research centres
4. Strategic collaboration
Strong RWD capabilities make hospitals valuable partners for pharmaceutical companies, payers, and academic researchers.
Why RWD matters to pharma
- Smarter clinical trials
Pharma can use RWD to find real-world patient cohorts, implement hybrid or decentralized trials, and use synthetic control arms – leading to faster, more cost-effective R&D. RWD also enhances feasibility assessments and accelerates the enrolment of eligible patients, improving overall trial efficiency.
- Regulatory and safety insights
Health authorities (e.g. FDA, EMA) increasingly accept RWE for label expansions, supplemental approvals, and long-term safety monitoring.
- Stronger market access strategy
RWD provides evidence of a therapy’s real-world performance and cost-effectiveness, which strengthens pricing, reimbursement, and payer negotiations.
- Drug lifecycle management
Through ongoing RWD analysis, pharma can identify new therapeutic indications, support off-label use cases, and explore opportunities for drug repurposing.
RWD brings value to both hospitals and pharma
Sqilline Health’s path from raw data to RWD and RWE
Our RWD-to-RWE methodology, powered by Danny Platform, ensures that real-world data is transformed into robust, scalable, and regulator-ready insights. This framework is designed to serve both healthcare providers and life science partners, with built-in flexibility to meet complex clinical or commercial objectives.
Workflow steps
- Initial stakeholder engagement
- Data quality assessment
- Clinical & technical recommendations
- Data structuring & harmonization
- Cohort / RWD set creation
- Analytics implementation
- Validation & peer review
- RWE generation & dissemination
Each step ensures that the evidence we produce is not only analytically sound but also clinically relevant, reproducible, and ready for regulatory or strategic use.
Call to action
Whether you represent a hospital aiming to improve care delivery and attract clinical trials, or a pharmaceutical company seeking to accelerate R&D, speed up approvals, and improve patient access – investing in RWD is no longer optional. It’s a strategic imperative for long-term success.
At Sqilline Health, we bring together the right process, the right people, and the right technology – with Danny Platform at the core – to help you turn data into decisions that matter.
Let’s talk. Contact us today to explore how we can support your journey – from raw data to real-world data and real-world evidence.
